Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.72 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 4/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12197799 | 0.86 | TSHR (0.63) | CRHBPCRHR2KMT2AMEN1TSHR | |
| SCHEMBL21497034 | 0.85 | CRHBP (0.58) | CRHBPCRHR2KMT2AMEN1TSHR | |
| SCHEMBL11872858 | 0.85 | DDX3X (0.71) | CRHBPCRHR2KMT2AMEN1TSHR | |
| SCHEMBL8309888 | 0.84 | CRHBP (1.00) | CRHBPCRHR2KMT2AMEN1CA2 | |
| SCHEMBL10715101 | 0.82 | CRHBP (0.60) | CRHBPCRHR2KMT2AMEN1CA2 | |
| SCHEMBL7570382 | 0.82 | TSHR (0.75) | KMT2AMEN1TSHRHTTLMNA | |
| SCHEMBL3791578 | 0.81 | TSHR (0.74) | CRHBPCRHR2KMT2AMEN1TSHR | |
| SCHEMBL18023815 | 0.81 | DDX3X (0.74) | CRHBPCRHR2KMT2AMEN1CA2 | |
| SCHEMBL21893366 | 0.81 | CA2 (0.62) | CRHBPCRHR2KMT2AMEN1TSHR | |
| SCHEMBL6563189 | 0.81 | CA2 (0.62) | CRHBPCRHR2KMT2AMEN1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3568390-B1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2013063100-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013060029-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013063100-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013060029-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20110243844-A1 | SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | MERCK SHARP & DOHME CORP. | 2011-10-06 | — | — | US | disclosed |
| EP-2334183-A1 | SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | Merck Sharp & Dohme Corp. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010033350-A1 | SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | MERCK & CO., INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | CRHBP 1911/4885CRHR2 4778/4885KMT2A 828/4885 |
| US-20110243844-A1 | SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | GRM4, GRIA4, GRM1 | CRHBP 566/4885CRHR2 346/4885KMT2A 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.